Form 8-K - Current report:
SEC Accession No. 0000950170-24-135381
Filing Date
2024-12-11
Accepted
2024-12-11 16:15:47
Documents
12
Period of Report
2024-12-06
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fdmt-20241206.htm   iXBRL 8-K 43618
2 EX-4.1 fdmt-ex4_1.htm EX-4.1 153530
  Complete submission text file 0000950170-24-135381.txt   342875

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20241206.xsd EX-101.SCH 25898
14 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20241206_htm.xml XML 4890
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 241541724
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)